Shionogi
Shionogi & Co., Ltd., commonly known as Shionogi, is a prominent pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, Shionogi has established itself as a leader in the pharmaceutical industry, focusing on research and development in areas such as infectious diseases, pain management, and central nervous system disorders. With a strong presence in Japan and expanding operations in North America and Europe, Shionogi is renowned for its innovative core products, including antiviral treatments and analgesics. The company’s commitment to advancing healthcare solutions has led to significant milestones, including the development of groundbreaking therapies that address unmet medical needs. Shionogi's dedication to quality and innovation has positioned it as a key player in the global pharmaceutical market, earning recognition for its contributions to public health and patient care.
DitchCarbon Score
How does Shionogi's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shionogi's score of 49 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Shionogi's reported carbon emissions
In 2023, Shionogi & Co., Ltd. reported total greenhouse gas emissions of approximately 214,942,000 kg CO2e. This figure includes 40,373,000 kg CO2e from Scope 1 emissions, 31,650,000 kg CO2e from Scope 2 emissions (market-based), and 142,919,000 kg CO2e from Scope 3 emissions. Over the years, Shionogi has demonstrated a commitment to reducing its carbon footprint, with significant targets set for the near future. The company has pledged to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 46.2% by the fiscal year 2030/31, using the fiscal year 2019/20 as a baseline. Additionally, Shionogi aims to cut its Scope 3 emissions from purchased goods and services by 20% within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are consistent with the reductions necessary to limit global warming to 1.5°C. Shionogi's emissions data reflects a proactive approach to climate action within the pharmaceutical sector, highlighting its commitment to sustainability and environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 43,456,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 46,681,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 196,761,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shionogi is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
